Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)

被引：0
|
作者：
Nelson, J. B.
Chin, J. L.
Love, W.
Schulman, C.
Sleep, D.
Qian, J.
Steinberg, J.
Hintzman, P.
Dawson, M.
Carducci, M.
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Urol Res Ctr, Burlington, ON, Canada
[4] Hop Erasme, Brussels, Belgium
[5] Abbott, Abbott Pk, IL USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase III trial of docetaxel (D), estramustine (E), and prednisone versus docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC)
    Machiels, J. H.
    Mazzeo, F.
    Clausse, M.
    Filleul, B.
    Marcelis, L.
    Honhon, B.
    D'Hondt, L.
    Dopchie, C.
    Bonny, M.
    Kerger, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Phase I/II study of weekly docetaxel and vinblastine in the treatment of hormone-refractory prostate cancer (HRPC).
    Ackler, JR
    Tester, WJ
    Leighton, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 771S - 771S
  • [33] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients
    Humphreys, M. R.
    Ma, C.
    Sridhar, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer
    Kolodziej, Michael
    Neubauer, Marcus A.
    Rousey, Steven R.
    Pluenneke, Robert E.
    Perrine, George
    Mull, Stephanie
    Boehm, Kristi A.
    Ilegbodu, Des
    Asmar, Lina
    CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 155 - 161
  • [35] NAVELBIN AS A SECOND LINE TREATMENT FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Jana, J. K.
    Rovny, A. R.
    Divisova, K. D.
    Filipensky, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 658 - 659
  • [36] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC)
    Kattan, Joseph G.
    Farhat, Fady S.
    Chahine, Georges Y.
    Nasr, Fady L.
    Moukadem, Walid T.
    Younes, Fariha C.
    Yazbeck, Nadine J.
    Ghosn, Marwan G.
    INVESTIGATIONAL NEW DRUGS, 2008, 26 (01) : 75 - 79
  • [37] Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC).
    Kantoff, P. W.
    Glode, L. M.
    Tannenbaum, S. I.
    Bilhartz, D. L.
    Pittman, W. G.
    Schuetz, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 100S - 100S
  • [38] Phase II randomized trial of docetaxel plus estramustine (BE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): A final report.
    Eymard, JC
    Joly, F
    Priou, F
    Zannetti, A
    Ravaud, A
    Kerbrat, P
    Mousseau, M
    Paule, B
    Touze, F
    Ecstein-Fraisse, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 407S - 407S
  • [39] Docetaxel (D) and estramustine (E) as first-line chemotherapy for patients (pts) with hormone-refractory advanced prostate cancer (HRPC): Final results of a multicentric phase II randomized trial
    Caffo, O.
    Sava, T.
    Comploj, E.
    Giampaolo, M.
    Zustovich, F.
    Segati, R.
    Sacco, C.
    Perin, A.
    Pappagallo, G.
    Valduga, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Gefitinib (G) plus prednisone (P) versus placebo (pl) plus prednisone in the treatment of hormone-refractory prostate cancer (HRPC): A randomized phase II trial
    Boccardo, F.
    Rubagotti, A.
    Tacchini, L.
    Lapini, A.
    Cruciani, G.
    De Rubertis, G.
    Battaglia, M.
    Conti, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345